4.6 Review

Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis

Related references

Note: Only part of the references are listed.
Review Oncology

The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

H. -D. Wu et al.

Summary: This study conducted a meta-analysis on the effect of metformin on esophageal cancer risk in type 2 diabetes mellitus patients. Results indicated that overall, metformin does not reduce esophageal cancer risk in type 2 diabetes mellitus patients, but there is a significant reduction in Asian populations that requires further clarification.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

Article Oncology

Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis

Holli A. Loomans-Kropp et al.

Summary: The use of common drugs, such as proton pump inhibitors, statins, non-steroidal anti-inflammatory drugs, or metformin, may reduce one's risk of developing esophageal adenocarcinoma. These results suggest that repurposing agents often used for common chronic conditions may be a new strategy for cancer prevention efforts.

CANCER PREVENTION RESEARCH (2021)

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Oncology

Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis

Yue Chen et al.

Summary: The use of PPI is negatively associated with the risk of progression to HGD/EAC in BE patients, and the risk of HGD/EAC can be reduced with the prolonged use of PPI. Sensitivity analysis showed the stable results of this meta-analysis, and no publication bias was detected.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Article Gastroenterology & Hepatology

Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study

Qiao-Li Wang et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Article Critical Care Medicine

Meta-Analysis

Adrian Hernandez et al.

CHEST (2020)

Article Oncology

Use of metformin and aspirin is associated with delayed cancer incidence

Joseph J. Y. Sung et al.

CANCER EPIDEMIOLOGY (2020)

Article Endocrinology & Metabolism

Metformin: historical overview

Clifford J. Bailey

DIABETOLOGIA (2017)

Article Medicine, Research & Experimental

Meta-analysis in clinical trials revisited

Rebecca DerSimonian et al.

CONTEMPORARY CLINICAL TRIALS (2015)

Review Biology

LKB1 and AMPK and the cancer-metabolism link - ten years after

D. Grahame Hardie et al.

BMC BIOLOGY (2013)

Article Oncology

Antitumor effect of metformin in esophageal cancer: In vitro study

Mitsuyoshi Kobayashi et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2013)

Editorial Material Public, Environmental & Occupational Health

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Andreas Stang

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)

Article Mathematical & Computational Biology

A basic introduction to fixed-effect and random-effects models for meta-analysis

Michael Borenstein et al.

RESEARCH SYNTHESIS METHODS (2010)

Article Medicine, General & Internal

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

Review Oncology

Insulin and insulin-like growth factor signalling in neoplasia

Michael Pollak

NATURE REVIEWS CANCER (2008)

Article Mathematical & Computational Biology

Quantifying heterogeneity in a meta-analysis

JPT Higgins et al.

STATISTICS IN MEDICINE (2002)

Article Mathematical & Computational Biology

Advanced methods in meta-analysis: multivariate approach and meta-regression

HC van Houwelingen et al.

STATISTICS IN MEDICINE (2002)